Scotiabank raised the firm’s price target on INmune Bio (INMB) to $23 from $22 and keeps an Outperform rating on the shares. The company’s management appears confident a Biologics License Application that will be filed with the FDA around the end of the year will be received positively, the analyst tells investors. Additionally, the firm believes a positive outcome of the XPRo Phase 2 trial is expected to read out in June, which would “completely dwarf” the CORDStrom commercial opportunity.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue